SEC filing record
Primary Source · SEC.gov

OS Therapies Inc

Platform / Operating Company2026 vintage506(b)
Latest signalNew Form D filerForm D · 2026-10-23Last filing 2026-10-23

Raised

$7M

Investors

9

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

AltStreet Analysis

·

Generated from EDGAR primary sources

OS Therapies Inc, a Delaware-incorporated company, filed this Form D on 2026-10-23 disclosing $7.2M raised from 9 investors under the Rule 506(b) exemption. The offering involves a mix of equity, options to acquire securities, and securities to be acquired, with no minimum investment amount disclosed and no sales commissions reported. No parent platform or related fund family was identified in available records.

This filing sits within the alternative_investment category as a privately placed equity/derivative-securities offering by an operating company rather than a pooled investment fund. The 506(b) exemption and $7.2M raise size with 9 investors (implying an average check near $800K) is consistent with a private growth-stage financing round rather than a broad retail syndication.

Data Flags

First Sale DateFirst sale date is not disclosed despite $7.2M already reported as sold, which is inconsistent with a pre-offering filing and leaves the actual sale timeline unverifiable from this filing alone.
Securities TypeFiling lists three distinct securities types simultaneously (Equity, Option to Acquire, Security to be Acquired), suggesting a structured round combining direct equity with contingent or convertible instruments.
Minimum InvestmentMinimum investment field is not disclosed on the filing, which is a routine omission for this optional Form D field.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001795091
Entity NameOS Therapies Inc
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address115 Pullman Crossing Road, Suite 103, Grasonville, MD 21638
Phone(410) 297-7793
Industry / Fund TypeBiotechnology
Securities TypeEquity, Option to Acquire, Security to be Acquired
First Sale Date—
Filing DateOctober 23, 2026
Accession Number0000921895-26-002846
Total Offering Amount$12,282,478
Total Amount Sold$7,172,429
Amount Remaining$5,110,049
Total Investors9
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$859,774 (to Ceros Financial Services, Inc.)
Finders' Fees$0
Proceeds to Related Persons$0
Revenue RangeDecline to Disclose
State (Issuer Address)MD
Amendment Count13 filings on record
Signed ByFrancis Knuettel II, Chief Financial Officer

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

8

latest Oct 23, 2026

Critical / warning

0 / 0

0 watch · 8 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

13

raising, lapsed, closed, dark, pre_sale

Latest event New filer · Oct 23, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 8 filing events with values and deltas, latest 2026-10-23, and alerts on the next one
  • 13 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-10-23: 2 related persons added and 1 removed against the filing of 2026-08-25; 9 now listed. The names are in the Terminal feed.

Paul Romness

Executive Officer, Director · Grasonville, MD

Robert Petit

Executive Officer · Grasonville, MD

Francis Knuettel II

Executive Officer · Grasonville, MD

John Ciccio

Director · Grasonville, MD

Avril McKean Dieser

Director · Grasonville, MD

Craig Eagle

Director · Grasonville, MD

Olivier Jarry

Director · Grasonville, MD

Theodore Search

Director · Grasonville, MD

Kerry Clem

Executive Officer · Grasonville, MD

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Ceros Financial Services, Inc.CRD 37869 on BrokerCheck

Associated broker-dealer: None · Rockville, MD · Soliciting in all states

Questions About OS Therapies Inc

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is OS Therapies Inc?

OS Therapies Inc is a Delaware corporation that filed a Form D with the SEC on October 23, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is OS Therapies Inc legit?

AltStreet does not rate legitimacy; it reports the public record. OS Therapies Inc filed a Form D with the SEC on October 23, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $7,172,429 sold to 9 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is OS Therapies Inc registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that OS Therapies Inc claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has OS Therapies Inc raised?

OS Therapies Inc reported $7,172,429 sold from 9 investors of a $12,282,478 total offering as of the Form D filed October 23, 2026.

Who can invest in OS Therapies Inc?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in OS Therapies Inc?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling OS Therapies Inc and how are they paid?

The Form D names Ceros Financial Services, Inc. (CRD 37869), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $859,774 and finders' fees as $0. Form D allows these to be estimates.

Who is behind OS Therapies Inc?

The Form D lists 9 related persons: Paul A. Romness, executive officer, director (Chairman, President and Chief Executive Officer); Robert G. Petit, executive officer (Chief Medical Officer and Chief Scientific Officer); Francis Knuettel II, executive officer (Chief Financial Officer); John Ciccio, director; Avril McKean Dieser, director; Craig Eagle, director; Olivier Jarry, director; Theodore F. Search, director, and 1 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is OS Therapies Inc located?

The issuer's address on its SEC filings is 115 Pullman Crossing Road, Suite 103, Grasonville, MD 21638. Its phone number of record is 410-297-7793. It is organized under the laws of Delaware.

How long is the OS Therapies Inc offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is OS Therapies Inc's revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.